STC-15 (a METTL3 inhibitor) is a Phase 2 monotherapy trial investigating the safety, tolerability, and anti-tumor activity of STC-15 in participants with selected, advanced sarcomas subtypes, including DDLPS.
The upLIFT study is a Phase 3 clinical trial for patients suffering from low blood sugar related symptoms (hypoglycemia) due to the over-production of hormones (e.g., insulin or similar substances) by certain non-removable tumors.
The SA53-OS Study is a phase 1/2a, open-label, dose escalation study. The objective of this MDM2 inhibitor trial is to assess safety and efficacy in adult participants with refractory solid tumors, including dedifferentiated liposarcoma.
The ATLAS (Actinium Therapy for Late-stage Aggressive Sarcomas) Study is an open-label study evaluating the safety, tolerability, and efficacy of the radiopharmaceutical, [Ac-225]-RTX-2358 targeting fibroblast activation protein‑α (FAP) in patients with relapsed or refractory soft tissue sarcomas.
The SARATOGA study is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL] ) in participants with previously treated advanced soft tissue sarcoma.
The EA7222 Study is a Randomized Phase 3 Trial of Doxorubicin (chemotherapy) + Pembrolizumab (immunotherapy) vs. Doxorubicin (chemotherapy) alone for the treatment of dedifferentiated liposarcoma (DDLPS).